Dataset Information

RT-22MRI AND FET PET FOR RADIOTHERAPY PLANNING IN RECURRENT HIGH-GRADE GLIOMA (HGG) IN A PROSPECTIVE PHASE I TRIAL

ABSTRACT: BACKGROUND AND PURPOSE: Re-irradiation of HGG at recurrence may be a viable treatment option for some patients. Positron emission tomography (PET) using the amino acid tracer, 18F-fluoro-ethyltyrosine (FET) may have higher specificity and sensitivity than MRI in this setting. Both FET PET and MRI were used for target delineation in a prospective trial. The purpose of this study was to evaluate the impact of FET PET on the radiotherapy target. MATERIAL AND METHODS: A phase I trial examined the safety of hypofractionated stereotactic re-irradiation at different dose levels. Patients in PS 0-2 with localized recurrence of HGG and no other treatment options were eligible. With MRI, tumor was manually contoured using T1 contrast enhanced sequences. For PET, a threshold of 1.6x mean in background was used in a semi-automatic segmentation procedure. The planning target volume for treatment was the combination of both tumor volumes (MRI and PET) plus a 2 mm margin. Matlab software was used for spatial analyses. (Trial identifier: NCT02025231). RESULTS: Twenty-eight patients were included (GBM: n = 22; grade 3 glioma: n = 6). All patients had received radiotherapy and temozolomide, and 61 % had previously received bevacizumab. Median tumor volume defined by MRI and PET was 34 cm3 (range: 0-230 cm3) and 24 cm3 (range:0-214 cm3), respectively. Using PET increased the total gross tumor volume by a median of 10 cm3 (range:0-77 cm3), compared to MRI alone. The median longest distance from the MRI-target to encompass the PET-target was 10 mm (range: 0.6 to 43 mm). CONCLUSION: Tumor volumes defined by MRI and PET were spatially separated by up to 43 mm indicating that large portions of PET positive tumor would be missed if the target was solely based on MRI (T1 + contrast). FET PET may be useful for tumor delineation in re-irradiation of HGG.

SUBMITTER: Moller S

PROVIDER: S-EPMC4218527 | biostudies-literature | 2014 Nov

REPOSITORIES: biostudies-literature

ACCESS DATA

Similar Datasets

Project description:Abstract BACKGROUND There is a lack of treatment options for HGG and LGG patients. BRAFV600E mutations are uncommon in glioma, with a poor long-term prognosis. Combined BRAF/MEK inhibition extends progression-free survival (PFS) and overall survival (OS) in BRAF V600E–mutated melanoma, non small-cell lung cancer, and anaplastic thyroid cancer. METHODS This phase 2, open-label trial (NCT02034110) evaluated dabrafenib (BRAF inhibitor, 150mg BID) plus trametinib (MEK inhibitor, 2mg QD) in patients with BRAF V600E mutations in 9 rare tumor types, including HGG and LGG. Eligible patients had histologically-confirmed recurrent or progressive glioma (LGG:WHO grade 1 or 2; HGG:WHO grade 3 or 4), with HGG patients required to have received radiotherapy and first-line chemotherapy, or concurrent chemoradiation. Treatment continued until unacceptable toxicity, disease progression, or death. Primary endpoint was investigator-assessed objective response rate (ORR) using RANO criteria. Secondary endpoints included duration of response (DOR), PFS, OS, and safety. RESULTS Interim analysis (IA) #14 (data cutoff: April 2, 2018) reported additional 3 months follow-up, with 49 patients enrolled (HGG, n=39; LGG, n=10) and 3 patients not evaluable for response. In HGG patients, ORR was 27% (10/37; 95%CI: 13.8%-44.1%), including CR (n=1), PR (n=9), and SD (n=11), with 16 patients currently ongoing treatment. In LGG patients, ORR was 56% (5/9; 95%CI: 26.8%-79.3%), including PR (n=5) and SD (n=4), with 6 patients currently ongoing treatment. OS, PFS, and DOR will be presented (IA#15). In HGG patients, adverse events (AEs) included fatigue (33%), headache (31%), rash (28%), and pyrexia (23%); grade 3/4 AEs included neutropenia (8%) and fatigue (5%). In LGG patients, AEs included headache (70%), fatigue, pyrexia (60% each), nausea, and arthralgia (50% each); grade 3/4 AEs included fatigue (20%). CONCLUSIONS Dabrafenib plus trametinib demonstrated promising efficacy in patients with recurrent or refractory BRAF V600E?mutated HGG or LGG, with manageable AEs and no new safety signals.

Dataset Information

RT-22MRI AND FET PET FOR RADIOTHERAPY PLANNING IN RECURRENT HIGH-GRADE GLIOMA (HGG) IN A PROSPECTIVE PHASE I TRIAL

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets